Navigation Links
In a childhood cancer, basic biology offers clues to better treatments
Date:11/9/2011

By studying tumor biology at the molecular level, researchers are gaining a deeper understanding of drug resistance -- and how to avoid it by designing pediatric cancer treatments tailored to specific mutations in a child's DNA. In a fruitful collaboration, pediatric oncologists and biochemists are targeting neuroblastoma, an often-deadly childhood cancer of the peripheral nervous system.

"This scientific study allows us to move ahead in improving drug treatments for children with a particular form of neuroblastoma," said study co-leader Yal P. Moss, M.D., a pediatric oncologist at The Children's Hospital of Philadelphia. Moss teamed up in this research with the study co-leader, Mark A. Lemmon, Ph.D., professor and chair of Biochemistry and Biophysics at the Perelman School of Medicine of the University of Pennsylvania.

"This has been a terrific collaboration," said Lemmon. "We have been working for a long time to understand how growth factor receptors work as signaling 'machines.' With the Moss group, we focused on how control of these receptors is compromised in cancer, and can use the laboratory results to guide directly where to go next in the clinic."

The study appears today in the Nov. 9 issue of Science Translational Medicine.

In neuroblastoma, the most common solid cancer of early childhood, roughly 10 percent of patients have mutations in ALK, the gene carrying the code for the signaling receptor anaplastic lymphoma kinase. Moss, who led a team that discovered this gene's role in 2008, was able to expedite a pediatric clinical trial based on this finding within a year, because an existing ALK inhibitor called crizotinib was already in adult clinical trials for a subset of non-small cell lung cancer patients.

Crizotinib was therefore available for use in a pediatric clinical trial against neuroblastoma, but early results in adult cancers showed that tumors sometimes develop resistance to the drug. The current study combined basic biochemistry and structural biology with studies in tumor-derived cell lines and animal models to investigate how different ALK mutations in neuroblastoma affect how ALK activity and tumor growth respond to crizotinib.

The researchers focused on the two most common ALK mutations found in neuroblastoma patients. They found that crizotinib effectively halted the proliferation of neuroblastoma cells harboring the most common mutation, but that the second most common ALK mutation was more resistant to the drug.

The reason for the different results, say the authors, is that the drug-resistant mutation causes ALK to bind more tightly to a key cellular compound called ATP that drives its signaling. Since crizotinib must displace this compound to inhibit ALK, the increased ATP binding caused by the resistant mutation reduces crizotinib's effectiveness.

The authors say these results justify increasing the dosage of crizotinib in patients with the more drug-resistant mutation, although human studies must first be performed to determine if a higher dose will be safe and effective in children. Fortunately, said Moss, unlike conventional chemotherapy, which attacks both cancerous and normal cells, this type of drug strikes much more specific targets, and tends to have lower risk of overall toxicity.

"This study shows how important it is to integrate basic science into the design of clinical trials, and how useful it can be," Moss added. "If we can better individualize treatment to a child's genetic profile by understanding the effects of mutations on protein structure and function, we may achieve better results for patients," added Lemmon.


'/>"/>
Contact: John Ascenzi
ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Related medicine news :

1. NIH scientists discover link among spectrum of childhood diseases
2. Childhood diet lower in fat and higher in fiber may lower risk for chronic disease in adulthood
3. Wayne State University to study effects of risky family environments on childhood asthma
4. Childhood asthma non-profit invests millions in health centers to help children better manage asthma
5. Vaccine for Childhood Diarrhea Helps Kids, Saves Dollars
6. Key regulatory genes often amplified in aggressive childhood tumor of the brainstem
7. White Houses Childhood Obesity Task Force must focus on providing treatment for minority children
8. Largest global childhood pneumonia etiology study launched
9. Unemployment Higher Among Childhood Cancer Survivors in Poor Health
10. Childhood maltreatment linked to long-term depression risk and poor response to treatment
11. Childhood Depression, Anxiety Tied to Pain in Adulthood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... The new ... medium and small physician practices, to better grasp and implement HIPAA’s privacy, security, ... guides practices on a well-defined, expert-created path to compliance. HIPAA Institute has positioned ...
(Date:5/2/2016)... ... May 03, 2016 , ... RNK ... sSOIP telemedicine stethoscope software that enables the stethoscope stream to go over the ... works with RNK’s flagship PCP-USB stethoscope. , Remote auscultation involves two software elements ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... ... 3, Issue 1 of Patient Experience Journal (PXJ), an international, open access, ... experience. With almost half the issue representing international (non-US) based authors, the third ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... The ... a time to honor the civilian nurses that care for its uniformed service members, ... signed a proclamation in 1974 designating May 6th through May 12th National Nurses Week. ...
(Date:5/2/2016)... ... May 02, 2016 , ... In honor of National Physical Fitness and ... people who share their fitness journey on social media. , The foot care ... award a $100 product voucher each week during May to one winner. , “Whether ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... of oral drug delivery systems, announced today that the Company ... Joseph Gunnar & Co. LLC, taking place on ... Nadav Kidron , CEO of Oramed, will present a ...   PIONEERS 2016, presented by Joseph Gunnar ...
Breaking Medicine Technology: